pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·5h ago·1 min read
save

Endpoints 11 showcases top biotech startups, signaling renewed optimism and funding

Sep 25, 2026·read at Endpoints ↗Positive

The Endpoints 11 awards highlight the most promising biotech startups of 2026, offering a snapshot of emerging trends in the sector.

According to the summary, the awards illustrate that biotech appears to be emerging from a period of uncertainty, with increased capital flowing to innovative companies.

The recognition serves as a barometer for investors and industry observers, pointing to where future breakthroughs and funding may concentrate.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Biotech's best startups of 2026: Meet this year's Endpoints 11”

read at Endpoints ↗
456 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoJury awards Nektar $90M in suit against LillyEndpoints
  • 2h agoPharma industry asks FDA for more details on when one trial is enoughEndpoints
  • 3h agoTo get drugmakers into ultra-rare disease, the answer isn’t rare disease at allEndpoints
  • 4h agoLegend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitEndpoints
  • 5h agoEndpoints 11 2026 winner Kali looked at China for pipeline drugs, then turned in-houseEndpoints